Voyager Medical Research

Company Overview

Snapshot

Founded in August 2015 by Daniel Cohn and Ariel Halevy, Voyager Medical Research operates with 1–10 employees. The company has raised $1.5M across one funding round. In January 2019, the company secured seed funding from Israel Innovation Authority.

Business overview

Voyager Medical Research specializes in developing proprietary polymers for medical applications, primarily focusing on preventing complications in abdominal wall surgery. Its flagship product, Voyager Surgical Suture (VSS), addresses the issue of Incisional Hernia post-laparotomy. The company's ACE Surgical Suture is a monofilament, absorbable surgical suture based on a unique co-polymer (PPCA) developed through six years of research at the Institute of Chemistry of the Hebrew University, offering extended abdominal wall support compared to competitor products. Voyager Medical Research operates within the Health Tech & Life Sciences sector, specifically targeting hospitals, surgeons, and healthcare providers globally.

Company Intelligence Q&A

What is Voyager Medical Research's primary product?

Voyager Medical Research's primary product is Voyager Surgical Suture (VSS), an absorbable monofilament suture designed for abdominal wall closure to prevent complications like Incisional Hernia.

When was Voyager Medical Research founded?

Voyager Medical Research was founded in August 2015.

Who are the co-founders of Voyager Medical Research?

Daniel Cohn and Ariel Halevy are the co-founders of Voyager Medical Research.

What is the key innovation behind Voyager Medical Research's ACE Surgical Suture?

The ACE Surgical Suture is based on a unique co-polymer called PPCA, which provides 5-6 months of abdominal wall support, significantly longer than competitor products, enabling more complete healing.

In which sector does Voyager Medical Research primarily operate?

Voyager Medical Research primarily operates in the Health Tech & Life Sciences sector, focusing on biomaterials and medical devices.